Recent

% | $
Quotes you view appear here for quick access.

Retrophin, Inc. Message Board

  • rrtzrealmd rrtzrealmd Feb 14, 2014 8:44 PM Flag

    The curious case of RE-021...

    ...originally it was developed by Bristol-Myers...in 2006, EIGHT YEARS ago, it was part of a group of compounds they licensed to Pharmacopeia...Pharmacopeia ran phase 1 and 2 trials as a possible treatment for hypertension...two years later, Ligand came along and bought Pharmacopeia for 70 million dollars...

    ...for the next FOUR YEARS, Ligand -- probably recognizing what an expensive black hole further development of sparsetan (aka RE-021) would be, totally ignored it -- UNTIL along came RTRX who acquired a license for it...

    ...and now:

    "Ligand will receive a net upfront payment of $1 million, and may receive, net of amounts owed to third parties, over $75 million in milestone payments based on clinical and regulatory progress as well as 9% in royalties on potential future worldwide sales by Retrophin."

    ...hmmmmmmmm...isn't it more USUAL for the tiny biotech to receive the "upfront payment" as well as the milestone payments from the bigger company for maneuvering a drug through trials?...

    ...as it is, RTRX investors won't start making a dime until profits from sales tops $76 million -- an event likely to occur about the same time that pigs start flying through snowstorms in Hades...HAW!!!...

    ...I accidentally posted this earlier as a reply to a question about RE-024 -- that was not spamming, just a mistake on my part.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Do you even know why RTRX is developing this drug? Do you know what FSGS is? Hint: its not hypertension.

      • 1 Reply to the_real_biotrader
      • ..."Focal Segmental Glomerulosclerosis (FSGS) is a disease that affects the kidney’s filtering system (glomeruli) causing scarring and loss of large amounts of protein in the urine."...satisfied?...

        ...and one of the odd things is that they AREN'T devloping it for hypertension since it has ALREADY completed phase 2 trials for that...I presume someone at Ligand felt it wasn't worth it...too bad for RTRX since there is a whole LOT more hypertensive disease than there is glomerulosclerosis...

        ...not to mention that they've found the agent thta triggers the cascade leading to the disease -- "suPAR" aka "soluble form of the urokinase plasminogen activator receptor"...plus the FDA just last year approved a device that can be used to treat patients that don't respond to the standard therapies -- the "Liposorber LA-15 System...although the study was small, the gizmo proved remarkably adept at inducing remission of the disease...but then, you probably already knew all that, huh?...

 
RTRX
15.00+1.27(+9.25%)May 4 4:00 PMEDT